IL292584A - Generation of cd38 knock-out primary and expanded human nk cells - Google Patents

Generation of cd38 knock-out primary and expanded human nk cells

Info

Publication number
IL292584A
IL292584A IL292584A IL29258422A IL292584A IL 292584 A IL292584 A IL 292584A IL 292584 A IL292584 A IL 292584A IL 29258422 A IL29258422 A IL 29258422A IL 292584 A IL292584 A IL 292584A
Authority
IL
Israel
Prior art keywords
cells
cell
cancer
subject
dara
Prior art date
Application number
IL292584A
Other languages
English (en)
Hebrew (he)
Original Assignee
Res Inst Nationwide Childrens Hospital
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital, Univ Johns Hopkins filed Critical Res Inst Nationwide Childrens Hospital
Publication of IL292584A publication Critical patent/IL292584A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL292584A 2019-10-31 2020-11-02 Generation of cd38 knock-out primary and expanded human nk cells IL292584A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962928524P 2019-10-31 2019-10-31
PCT/US2020/058565 WO2021087466A1 (en) 2019-10-31 2020-11-02 Generation of cd38 knock-out primary and expanded human nk cells

Publications (1)

Publication Number Publication Date
IL292584A true IL292584A (en) 2022-06-01

Family

ID=75715400

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292584A IL292584A (en) 2019-10-31 2020-11-02 Generation of cd38 knock-out primary and expanded human nk cells

Country Status (11)

Country Link
US (1) US20220401482A1 (cg-RX-API-DMAC7.html)
EP (1) EP4051297A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022554284A (cg-RX-API-DMAC7.html)
KR (1) KR20220093337A (cg-RX-API-DMAC7.html)
CN (1) CN114867485A (cg-RX-API-DMAC7.html)
AU (1) AU2020375053A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022008215A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156509A1 (cg-RX-API-DMAC7.html)
IL (1) IL292584A (cg-RX-API-DMAC7.html)
MX (1) MX2022005051A (cg-RX-API-DMAC7.html)
WO (1) WO2021087466A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
MX2023014356A (es) * 2021-06-02 2024-02-15 Metagenomi Inc Sistemas crispr de clase ii, tipo v.
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
WO2023081200A2 (en) * 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Cd38 compositions and methods for immunotherapy
JP2025001053A (ja) * 2021-11-05 2025-01-08 学校法人東海大学 劇症型ｎｋ白血病に対する治療標的の同定
KR20250029015A (ko) 2022-03-07 2025-03-04 사노피-아벤티스 유.에스. 엘엘씨 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도
CN114921416B (zh) * 2022-05-12 2023-05-23 广东普罗凯融生物医药科技有限公司 一种nk细胞及其制备方法
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024124242A2 (en) * 2022-12-09 2024-06-13 Research Institute At Nationwide Children's Hospital Combination cd38ko/car ki nk cell immunotherapy for dual targeting with cd38 monoclonal antibodies
US20260207666A1 (en) * 2022-12-09 2026-07-23 Research Institute At Nationwide Children's Hospital Cd38 as integration site for enhanced function of gene-modified immune cells
EP4651880A1 (en) * 2023-01-17 2025-11-26 Research Institute at Nationwide Children's Hospital Methods of targeting glycogen synthase kinase 3 beta in nk cells
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品
WO2025213127A1 (en) 2024-04-05 2025-10-09 Indapta Therapeutics, Inc. Treatment of autoimmune diseases or conditions with natural killer cells
WO2025245399A1 (en) 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells
WO2026050706A1 (en) * 2024-08-30 2026-03-05 Aventis Inc. Nk cells having reduced cd38 expression and method for producing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US128A (en) 1837-02-16 Holdback for sleds
FR1601438A (cg-RX-API-DMAC7.html) 1968-10-17 1970-08-24
US10117899B2 (en) * 2013-10-17 2018-11-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
EP3154581B1 (en) * 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US10738278B2 (en) * 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
JP6754361B2 (ja) * 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
JP7033453B2 (ja) * 2015-06-30 2022-03-10 セレクティス 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
JP7653759B2 (ja) * 2016-01-20 2025-03-31 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
AU2017248259A1 (en) * 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
EP3581190B1 (en) * 2016-12-09 2021-03-10 ONK Therapeutics Limited Engineered natural killer cells and uses thereof
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
AU2019271366B2 (en) * 2018-05-16 2026-02-26 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins

Also Published As

Publication number Publication date
US20220401482A1 (en) 2022-12-22
AU2020375053A1 (en) 2022-05-26
CN114867485A (zh) 2022-08-05
KR20220093337A (ko) 2022-07-05
MX2022005051A (es) 2022-08-08
CA3156509A1 (en) 2021-05-06
BR112022008215A2 (pt) 2022-07-12
JP2022554284A (ja) 2022-12-28
EP4051297A4 (en) 2023-10-18
EP4051297A1 (en) 2022-09-07
WO2021087466A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
US20220401482A1 (en) Generation of cd38 knock-out primary and expanded human nk cells
Ruella et al. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Rovatti et al. Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation
Campbell et al. Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma
Witkowski et al. Immune-based therapies in acute leukemia
Velardi et al. Sex steroid blockade enhances thymopoiesis by modulating Notch signaling
US20210228630A1 (en) Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
CN108026512B (zh) 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
AU2018336522B2 (en) A gRNA targeting HPK1 and a method for editing HPK1 gene
Saravia et al. Immunometabolism of regulatory T cells in cancer
GB2605883A (en) Tumor infiltrating lymphocytes and methods of therapy
He et al. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer
KR20150131218A (ko) T 세포 증식의 제어 방법
JP2023182711A (ja) 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ－ｃａｓ９編集のための方法、組成物および構成要素
JP2022546282A (ja) Ｇｏｌｄ制御導入遺伝子による併用療法
US12540311B2 (en) Crispr-based FOXP3 gene engineered t cells and hematopoietic stem cell precursors to treat IPEX syndrome patients
Fu et al. IL-2–inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells
EP3724327A2 (en) Subject-specific tumor inhibiting cells and the use thereof
Lundh et al. Next-generation CAR T cells to overcome current drawbacks
JP2024536188A (ja) 抗ｔｎｍｕｃ１ ｇｏｌｄ ｃａｒ ｔ細胞用の組成物および方法
Li et al. CAR-X cell engineering
RU2808035C2 (ru) Образование нокаутных первичных и размноженных nk-клеток человека с использованием рибонуклеопротеинов cas9
Sarkar Enzymatic depletion of adenosine to potentiate cancer immunotherapy.
de Lima et al. Genome Editing for Engineering the Next
HK40107105A (en) Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies